Liraglutide (Saxenda) Gets Okay From EU for Obesity Liraglutide (Saxenda) Gets Okay From EU for Obesity

The injectable GLP-1 agonist liraglutide, long available for the treatment of type 2 diabetes, nears the market in Europe for weight loss, hard on the heels of its US approval for the same indication. International Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news